Your Cart is Empty
Start shopping
MOUNJARO® 5mg KwikPen®, 1 Stk. (English Alternative)
Tier
| Packs | Discount (%) | For Each |
|---|---|---|
| 1 - 3 | — | $499.00 |
| 4 - 10 | 12.02 % | $439.00 |
| 11 - 20 | 14.03 % | $429.00 |
| 21+ | 16.03 % | $419.00 |
Shop with Confidence: Product Authenticity is Guaranteed
All products available at Doctor Medica shop are obtained from respective manufacturers and contain original LOT numbers Contact us if you have any questions about product LOT numbers.
MOUNJARO® 5mg KwikPen is a tirzepatide solution for injection from Eli Lilly and Company Limited, formulated as a once-weekly dual GIP and GLP-1 receptor agonist. The 5mg dose is the first titration step after the initial 2.5mg starting dose and is supplied as 1 KwikPen with 4 pre-filled doses. Are you looking to buy MOUNJARO® 5mg KwikPen online? Licensed professionals can contact Doctor Medica staff for guidance on sourcing, documentation, and ordering.
Product Specifications
- Active Ingredient: Tirzepatide
- Strength: 5mg per dose
- Dosage Form: 5mg solution for injection; 1 KwikPen with 4 pre-filled doses
- Packaging Note: This page describes an English-language packaging presentation used in certain international markets, including India; this is a descriptive packaging distinction rather than a regulatory classification
- Manufacturer: Eli Lilly and Company Limited
- Brand: MOUNJARO®
- Country of Origin: United States
- FDA Approval Date: Initial US approval in 2022 for MOUNJARO® (tirzepatide) injection [3]
- Drug Class: Injectable dual GIP/GLP-1 receptor agonist
- Storage Requirements: Store refrigerated at 2°C to 8°C before use; do not freeze. After first use, the KwikPen may be stored unrefrigerated for up to 30 days at temperatures not above 30°C, according to UK product information. [5]
- Package Dimensions: Width: 60mm | Height: 40mm | Length: 150mm | Weight: 60g
What is MOUNJARO® 5mg KwikPen English Alternative?
MOUNJARO® 5mg KwikPen contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is manufactured by Eli Lilly and Company Limited and, per UK product information, is supplied as a multi-dose, pre-filled KwikPen delivering four 5mg doses, each in 0.6mL of solution. [5] The 5mg strength is the first titration dose, typically introduced after approximately 4 weeks of 2.5mg treatment. In US prescribing information, MOUNJARO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes. [3] The active ingredient, strength, and mechanism of action are consistent with tirzepatide as approved elsewhere; local labeling, indication scope, device presentation, and authorization pathway should be verified against the applicable market's own current regulatory documentation before clinical use or procurement.English Alternative Packaging and India Market Context
In India, CDSCO's Subject Expert Committee (SEC) recommended import and marketing permission for tirzepatide in single-dose prefilled pen and single-dose vial presentations, across six strengths (2.5mg to 15mg), for chronic weight management, at its meeting dated June 19, 2024 — subject to the condition that the manufacturer conduct a Phase IV clinical trial in India. [4] Press coverage of the Indian market subsequently reported that Eli Lilly introduced Mounjaro in India in vial form in March 2025, initially limited to the 2.5mg and 5mg strengths. Separate press coverage later reported that Eli Lilly received approval for the Mounjaro KwikPen presentation in India in late June 2025, described as a multi-dose, single-patient-use, prefilled pen delivering four fixed doses per pen, available across the same six strengths (2.5mg to 15mg), with an indication described in that coverage as adjunctive treatment for type 2 diabetes and for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. For licensed professionals reviewing English alternative packaging, the key distinction is market presentation rather than active ingredient: the medicine itself remains tirzepatide, but packaging, labeling, the locally approved indication, and the applicable authorization pathway may differ from US or UK/EU versions. Current local labeling and CDSCO documentation should be verified directly before procurement or clinical use in any India-market context, since this summary reflects publicly reported regulatory and press information rather than a full review of primary CDSCO records for every presentation and date.2026 KwikPen Redesign & Differentiation from Previous Models
Eli Lilly rolled out an updated MOUNJARO® KwikPen device across markets in April 2026. The update involves only the pen's internal hardware — tirzepatide's concentration, formulation, and active ingredient remain unchanged. A new internal component positioned behind the plunger extends its resting length, so that after the fourth and final dose is delivered, the plunger sits closer to the end of the pen, providing a clearer visual indication that the device is ready for disposal. This design change is intended to eliminate the so-called "golden dose" — residual liquid that some patients previously withdrew and used as an unofficial fifth dose. For English alternative packaging specifically, clinics and pharmacists sourcing internationally packaged products should confirm which device generation a given shipment represents, since hardware updates may roll out to different markets on different timelines. Practitioners should continue to reinforce that each KwikPen is designed to deliver exactly four prescribed doses, regardless of device generation or packaging market.Mechanism of Action
Tirzepatide acts via simultaneous agonism at GIP and GLP-1 receptors. GLP-1 receptor activation increases glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and supports postprandial glucose control. GIP receptor activation further potentiates insulin secretion and contributes to metabolic effects relevant to body weight. [3][5] In clinical trials, tirzepatide has been associated with dose-dependent reductions in body weight and improvements in glycemic control, including reductions in HbA1c, with gastrointestinal adverse events being the most common tolerability concern across dose levels. [1][2] Dose escalation from the 5mg strength should be based on tolerability, clinical response, and current prescribing information. [3]Indications & Clinical Use
MOUNJARO® is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; it is not indicated for type 1 diabetes. In the US, this indication applies to adults and pediatric patients aged 10 and older. The US label does not carry a chronic weight-management indication under the Mounjaro brand — tirzepatide's US weight-management approval is granted separately under the Zepbound® brand. [3] In India, CDSCO's SEC recommended import and marketing permission for the single-dose pen-and-vial presentations specifically for chronic weight management in June 2024. [4] Press coverage of the later KwikPen launch described its indication as covering both type 2 diabetes and chronic weight management in eligible adults. Practitioners reviewing English alternative packaging should verify the current, locally approved indication and label directly against CDSCO documentation before use, since the indication scope and supporting evidence can differ by market and by device presentation. The 5mg strength represents the first escalation step after the 2.5mg initiation dose. Before advancing the dose of MOUNJARO®, clinicians should assess gastrointestinal tolerability, renal function, and baseline status of diabetic retinopathy, and should not use MOUNJARO® as a substitute for insulin in insulin-requiring patients. [3]Administration & Injection Guidelines
MOUNJARO® 5mg KwikPen is administered once weekly by subcutaneous injection into the abdomen, thigh, or back of the upper arm, and may be given at any time of day, with or without food. Injection sites should be rotated with each dose; patients should avoid areas that are tender, bruised, scarred, or inflamed. [3][5] For professionals reviewing how to use MOUNJARO® KwikPen 5mg, the device is intended to be used strictly according to its current instructions for use for the specific market and packaging presentation. In general terms, this involves checking the pen label and confirming the correct strength and packaging, selecting a clean injection site, preparing the device, inserting the needle, pressing the dose button, and holding the pen in place until dose delivery is confirmed. Product-specific instructions for use should always be followed rather than relying on this general summary; this is especially relevant for English alternative packaging, where device instructions may be presented in a different format than US or UK/EU labeling. [5] MOUNJARO® interacts minimally with foods or drinks — no specific dietary restrictions are required on the label, though a reduced-calorie diet is typically used as an adjunct. Because tirzepatide delays gastric emptying, it may affect the absorption of oral medications, particularly time-sensitive drugs or those with a narrow therapeutic index. If a dose is missed, product instructions generally advise administering it within 4 days of the missed dose; if more than 4 days have passed, skip the missed dose and resume the regular weekly schedule without doubling the next dose. [3]Side Effects & Safety
Common side effects of MOUNJARO® include nausea, vomiting, diarrhea, decreased appetite, constipation, and abdominal discomfort. These effects are predominantly gastrointestinal and dose-related, tend to peak during treatment initiation and dose escalation, and are typically self-limiting; they should still be monitored in patients at risk of dehydration, with frailty, renal impairment, or concomitant medicines that may worsen fluid loss. [1][2] Serious but less common risks include pancreatitis, gallbladder disease, hypoglycemia when used with insulin or insulin secretagogues, hypersensitivity reactions, and kidney damage associated with dehydration from severe nausea, vomiting, or diarrhea. Diabetic retinopathy should also be considered in patients experiencing rapid glycemic improvement. [3] If a patient accidentally uses too much MOUNJARO®, medical assessment should be arranged promptly, as overdose may increase the risk of gastrointestinal adverse events and hypoglycemia, particularly when used alongside other glucose-lowering medicines. MOUNJARO® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, in patients with multiple endocrine neoplasia syndrome type 2, and in those with hypersensitivity to tirzepatide or any formulation component. Current prescribing information and the applicable local label should be reviewed to ensure that contraindications and safety data are complete. [3]MOUNJARO® KwikPen 5mg Price and Legal Status
MOUNJARO® is a prescription-only pharmaceutical product. In the US, MOUNJARO® is FDA-approved for glycemic control in type 2 diabetes; it does not carry a US chronic weight-management indication under the Mounjaro brand, as that indication is approved separately under Zepbound®. [3] In India, CDSCO's SEC recommended import and marketing permission for tirzepatide's single-dose pen and vial presentations for chronic weight management in June 2024, subject to a Phase IV clinical trial condition; press coverage separately reported CDSCO approval and commercial launch of the multi-dose KwikPen presentation in India in late June 2025. [4] This content is current as of July 1, 2026; practitioners should verify current prescribing information, primary CDSCO documentation, approved indications, and jurisdiction-specific label requirements before clinical use. MOUNJARO® KwikPen 5mg price may vary by market, account status, pack configuration, cold-chain handling requirements, packaging variant, and documentation needs. Licensed professionals can contact the Doctor Medica staff to inquire about wholesale buying options and to confirm product availability, documentation, and ordering requirements. Those interested in MOUNJARO® KwikPen wholesale should verify authenticity documentation, storage procedures, English alternative packaging details, and jurisdiction-specific prescribing requirements when buying online. Procurement teams building out a broader obesity-care portfolio alongside tirzepatide may also want to buy weight loss products as part of the same sourcing review.Citations
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Tian Q, Song Y, Deng Y, Lin S. Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis. Frontiers in Endocrinology. 2025. https://pubmed.ncbi.nlm.nih.gov/40747302/
- US Food and Drug Administration. MOUNJARO® (tirzepatide) injection, for subcutaneous use — Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
- Central Drugs Standard Control Organisation (India), Subject Expert Committee (Endocrinology & Metabolism). 2024. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Recommendations%20Endocrinology%20&%20Metabolism%2019.06.2024.pdf
- Eli Lilly and Company Limited. Mounjaro KwikPen 5mg Solution for Injection in Pre-filled Pen — Summary of Product Characteristics / Patient Leaflet. Electronic Medicines Compendium. 2026. https://www.medicines.org.uk/emc/product/15481/smpc
FAQ
MOUNJARO® 5mg KwikPen is a multi-dose, pre-filled pen containing tirzepatide, a dual GIP and GLP-1 receptor agonist from Eli Lilly and Company Limited.
The English alternative version refers to packaging and market presentation, not a different active ingredient. The product should still contain tirzepatide and must be checked against the relevant label, batch details, storage requirements, and jurisdiction-specific authorization. Licensed professionals should verify documentation before clinical use. [5]
Yes. Press coverage reported that Eli Lilly introduced Mounjaro in India in vial form in March 2025, and later launched the multi-dose KwikPen presentation following CDSCO review, in late June 2025. Practitioners should verify current CDSCO-authorized labeling and local prescribing requirements directly before use. [4]
The 2026 redesign updates the device hardware and internal plunger mechanism, while the medicine itself remains unchanged. The updated pen is intended to make the end of the fourth prescribed dose clearer and reduce confusion around residual liquid. Practitioners should continue to instruct patients that each KwikPen contains only 4 prescribed doses.
MOUNJARO® KwikPen 5mg is injected subcutaneously once weekly into the abdomen, thigh, or back of the upper arm, with injection sites rotated each dose. The current instructions for use for the specific market and packaging presentation should always be followed. [3][5]
Common side effects include nausea, vomiting, diarrhea, reduced appetite, constipation, and abdominal discomfort, most often during initiation or escalation and predominantly gastrointestinal and dose-related. [1][2] Practitioners should monitor for symptoms of pancreatitis, dehydration, kidney damage, and hypoglycemia in patients using insulin or insulin secretagogues. [3]
Yes. MOUNJARO® delays gastric emptying and may affect the absorption of oral medications, including time-sensitive drugs and those with a narrow therapeutic index. Clinicians should also assess concomitant use of insulin or insulin secretagogues. [3]
The MOUNJARO® KwikPen 5mg price depends on market, account status, sourcing requirements, packaging variant, and cold-chain handling needs. Licensed professionals can contact Doctor Medica staff for current guidance, documentation, and wholesale account information.
